213 related articles for article (PubMed ID: 24366444)
1. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway.
Ma YC; Li C; Gao F; Xu Y; Jiang ZB; Liu JX; Jin LY
Oncol Rep; 2014 Mar; 31(3):1343-9. PubMed ID: 24366444
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and apoptotic effect of epigallocatechin-3-gallate on Ishikawa cells is accompanied by sex steroid receptor downregulation.
Park SB; Bae JW; Kim JM; Lee SG; Han M
Int J Mol Med; 2012 Nov; 30(5):1211-8. PubMed ID: 22923012
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
[TBL] [Abstract][Full Text] [Related]
5. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines.
Masuda M; Suzui M; Weinstein IB
Clin Cancer Res; 2001 Dec; 7(12):4220-9. PubMed ID: 11751523
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex.
Lim YC; Cha YY
J Surg Oncol; 2011 Dec; 104(7):776-80. PubMed ID: 21725973
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Masuda M; Suzui M; Lim JT; Weinstein IB
Clin Cancer Res; 2003 Aug; 9(9):3486-91. PubMed ID: 12960141
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells.
Adachi S; Nagao T; Ingolfsson HI; Maxfield FR; Andersen OS; Kopelovich L; Weinstein IB
Cancer Res; 2007 Jul; 67(13):6493-501. PubMed ID: 17616711
[TBL] [Abstract][Full Text] [Related]
9. The phyto-chemical (-)-epigallocatechin gallate suppresses gene expression of epidermal growth factor receptor in rat hepatic stellate cells in vitro by reducing the activity of Egr-1.
Fu Y; Chen A
Biochem Pharmacol; 2006 Jul; 72(2):227-38. PubMed ID: 16750517
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis.
Gao F; Li M; Liu WB; Zhou ZS; Zhang R; Li JL; Zhou KC
Oncol Rep; 2015 Mar; 33(3):1533-9. PubMed ID: 25591943
[TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
[TBL] [Abstract][Full Text] [Related]
12. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
[TBL] [Abstract][Full Text] [Related]
13. The effect of green tea extract and EGCG on the signaling network in squamous cell carcinoma.
Liu X; Zhang DY; Zhang W; Zhao X; Yuan C; Ye F
Nutr Cancer; 2011; 63(3):466-75. PubMed ID: 21391127
[TBL] [Abstract][Full Text] [Related]
14. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.
Shimizu M; Deguchi A; Joe AK; Mckoy JF; Moriwaki H; Weinstein IB
J Exp Ther Oncol; 2005; 5(1):69-78. PubMed ID: 16416603
[TBL] [Abstract][Full Text] [Related]
15. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
16. [Epigallocatechin-3-gallate induces G1 phase cell cycle arrest in KB cells].
Jiang S; Chen XL; Ding Y; Chen ZW; Zhu LJ; Feng H; Zhen MC; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1381-3. PubMed ID: 19620059
[TBL] [Abstract][Full Text] [Related]
17. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
18. EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest.
Deng YT; Lin JK
J Agric Food Chem; 2011 Dec; 59(24):13318-27. PubMed ID: 22082235
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells.
Hou Z; Sang S; You H; Lee MJ; Hong J; Chin KV; Yang CS
Cancer Res; 2005 Sep; 65(17):8049-56. PubMed ID: 16140980
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate suppresses growth of AZ521 human gastric cancer cells by targeting the DEAD-box RNA helicase p68.
Tanaka T; Ishii T; Mizuno D; Mori T; Yamaji R; Nakamura Y; Kumazawa S; Nakayama T; Akagawa M
Free Radic Biol Med; 2011 May; 50(10):1324-35. PubMed ID: 21277973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
